Maintenance Therapy Using Lenalidomide in Myeloma

Study acronym: IFM2005-02
StatusCompleted
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Publications: details revised at 1 of 2 entriesv18
  2. Trial status: Active, Not Recruiting to Completed
    • Study completion date changed from estimate of Sep 2020 to Sep 2018
    v17
  3. Study completion date: Sep 2017 to Sep 2020
    • Study sites revised (77)
    • Publications: details revised at 1 of 2 entries
    v16
  4. Primary and study completion dates: Sep 2016 to Sep 2017
    • Collaborators revised (2)
    v15
  5. Primary and study completion dates: Sep 2015 to Sep 2016v14
Show 12 earlier versionsHide 12 earlier versions
  1. Primary and study completion dates pushed to Sep 2015v13
  2. Re-verified, no change to tracked fieldsv12
  3. Primary completion date: Feb 2012 to Feb 2015
    • Study completion date: Jun 2012 to Jun 2015
    • Eligibility criteria shortened, about 4 words
    v11
  4. Primary completion date: Feb 2011 to Feb 2012
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Jun 2013 to Jun 2012
    • Site details revised at 77 of 77 sites
    v10
  5. Trial status: Active, Not Recruiting to Recruiting
    • Site details revised at 77 of 77 sites
    v9
  6. Primary completion date: Jun 2009 to Feb 2011
    • Study sites: 2 to 77
    • Study completion date: Jun 2010 to Jun 2013
    v8
  7. Study Status, Conditions, Eligibilityv7
  8. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 2 of 2 sites
    v6
  9. Re-verified, no change to tracked fieldsv5
  10. Primary completion date: Jun 2009
    • Study completion date: Jun 2009 to Jun 2010
    • Secondary endpoints revised (3)
    v4
  11. Re-verified, no change to tracked fieldsv3
  12. Interventions: Revlimid (Drug) to lenalidomide (Drug), placebo (Drug)
    • Study arms: 0 to 2
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Maintenance treatment of myeloma.
Trial Details
NCT Number NCT00430365
Lead Sponsor University Hospital, Toulouse
Collaborators: Intergroupe Francophone du Myelome, Celgene
Conditions
(from sponsor)		 Myeloma
Related terms Neoplasms, Plasma Cell
Enrollment 614 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov